309912-57-0

Basic information

• Product Name: (5S)-5-(N,N-dibenzylamino)piperidin-2-one
• Synonyms: (5S)-5-(N,N-dibenzylamino)piperidin-2-one
• CAS NO: 309912-57-0
• Molecular Weight: 294.396
• Mol File: 309912-57-0.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (5S)-5-(N,N-dibenzylamino)piperidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (5S)-5-(N,N-dibenzylamino)piperidin-2-one(309912-57-0)
• EPA Substance Registry System: (5S)-5-(N,N-dibenzylamino)piperidin-2-one(309912-57-0)

Safety Data

• Hazardous Substances Data: 309912-57-0(Hazardous Substances Data)

Upstream product

• 161561-97-3 Methanesulfonic acid (S)-2-dibenzylamino-4-methanesulfonyloxy-butyl ester 
• 672883-95-3 4-(S)-amino-δ-valerolactam hydrochloride 
• 100-39-0 benzyl bromide 
• 309912-50-3 (3S)-methanesulfonic acid 4-phthalimido-3-(N,N-dibenzylamino)butyl ester 
• 309912-52-5 (4S)-4-(N,N-dibenzylamino)-5-phthalimidopentanenitrile 
• 137428-32-1 (2S)-2-[bis(phenylmethyl)amino]-1,4-butanediol 
• 309912-55-8 (4S)-5-amino-4-(N,N-dibenzylamino)pentanenitrile 

Downstream Products

• 309912-58-1 (5S)-5-(N,N-dibenzylamino)-2-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 309912-59-2 (5S)-1-benzyl-5-(N,N-dibenzylamino)-piperidin-2-one 
• 1143576-01-5 (S)-5-dibenzylamino-1-methylpiperidin-2-one 
• 1146362-34-6 (S)-5-dibenzylamino-1-propylpiperidin-2-one 
• 1146362-52-8 (S)-5-dibenzylamino-1-(4-fluorobenzyl)-piperidin-2-one 
• 309912-80-9 (5S)-[5-(N,N-acetylbenzylamino)-2-oxopiperidin-1-yl]acetic acid ethyl ester 
• 309912-79-6 (5S)-5-(N-benzylamino-2-oxopiperidin-1-yl)acetic acid ethyl ester 
• 309912-78-5 (5S)-5-(N,N-dibenzylamino-2-oxopiperidin-1-yl)acetic acid ethyl ester 

Relevant articles and documents

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryland wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to novel dihydrothienopyrimidines of the formula 1, and to pharmacologically acceptable salts thereof, formula (1) in which X is SO or SO2, but preferably SO, and either R3 is a monosubstituted phenyl ring in the ortho position or in the meta position, or R3 is a phenyl ring bisubstituted in any positions, and pharmaceutical compositions which comprise these compounds. These novel dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal symptoms or disorders, inflammatory disorders of the joints, of the skin or of the eyes, disorders of the peripheral or central nervous system or cancers.